Screening tests for inflammatory activity: applications in rheumatology

References

• Volanakis JE. Acute-phase proteins in rheumatic disease. In: Koopmann WJ, Moreland LW, editors. Arthritis and allied con-ditions. 15th ed. Philadelphia: Lippincott William & Wilkins; 2005. p. 504–16.
   Google Scholar
• Kushner I, Gabay C. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.
   Google Scholar
• James K. Cellular and humoral mediators of inflammation: non-specific humoral response to inflammation. In: McClatchey KD, editor. Clinical laboratory medicine. 2nd ed. Philadelphia: Lippincott Willians & Wilkins; 2002. p. 1430–46.
   Google Scholar
• de Carvalho JF, Hanaoka B, Szyper-Kravitz M, Shoenfeld Y. C-reactive protein and its implications in systemic lupus erythe-matosus. Acta Reumatol Port. 2007;32:317–22.
   PubMed Web of Science ®Google Scholar
• Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response: implications for systemic autoimmu-nity. J Exp Med. 2000;192(9):1353–63.
   PubMed Web of Science ®Google Scholar
• Mold C, Baca R, Du Clos TW. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fc. receptors. J Autoimmun. 2002;19:147–54.
   Google Scholar
• Atkinson JP. C-reactive protein: a rheumatologist's friend revis-ited. Arthritis Rheum. 2001;44(5):995–6.
   Google Scholar
• Sheldon J. Laboratory testing in autoimmune rheumatic diseases. Best Pract Res Clin Rheumatol. 2004;18(3):249–69.
   Google Scholar
• Kushner I. C-reactive protein elevation can be caused by condi-tions other than inflammation and may reflect aging. Cleve Clin J Med. 2001;68:535.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A. The role of laboratory in the evaluation of rheu-matic diseases. Clin Cornerstone. 1999;2(2):11–25.
   PubMedGoogle Scholar
• Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001;47(3):403–11.
   Google Scholar
• Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008; 121(10A):53–8.
   Google Scholar
• Collares GB, Vidigal PG. Recomendagoes para o uso da veloc-idade de hemossedimentação. Rev Med Minas Gerais. 2004; 14(1):52–7.
   Google Scholar
• Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501–23.
   PubMedGoogle Scholar
• Jense LE, Whitehead AS. Regulation of serum amyloid A protein expression during acute-phase response. Biochem J. 1998; 334:489–503.
   Google Scholar
• Marhaug G, Dowton SB. Serum Amyloid A: an acute phase apolipoprotein and precursor of AA amyloid. Baillieres Clin Rheumatol. 1994;8(3):553–73.
   PubMedGoogle Scholar
• Hochepied T, Berger FG, Baumann H, Libert C. al-acid glyco-protein: an acute-phase protein with inflammatory and immuno-modulating properties. Cytokine Growth Factor Rev. 2003; 14:25–34.
   PubMed Web of Science ®Google Scholar
• Fournier T, Medjoubi-N N, Pourquet D. Alpha-l-acid glycopro-tein. Biochim Biophys Acta. 2000;1482:157–171.
   PubMed Web of Science ®Google Scholar
• O'Connel TX, Horite TJ, Kasravi B. Understanding and inter-preting serum protein electrophoresis. Am Fam Phys. 2005;71(1): 105–12.
   Google Scholar
• Meijvis SC, Endeman H, Geers AB, ter Borg RI. Extremely high serum ferritin levels as diagnostic tool in adult-onset Still's dis-ease. Neth J Med. 2007;65(6):212–4.
   Google Scholar
• Yamanishi H, Kimura S, Hata N, Iyama S, Kanakura Y, Iwatani Y. Evaluation of a model of latent pathologic factor in relation to serum ferritin elevation. Clin Biochem. 2007;40: 359–64.
   Google Scholar
• Schwarz-Eywill M, Heilig B, Bauer H, Breitbart A, Pezzutto A. Evaluation of serum ferritin as a marker for adult Still's disease activity. Ann Rheum Dis. 1992;51:683–5.
   Google Scholar
• Lee MH, Means RT Jr. Extremely elevated serum ferritin levels in a university hospital: associated diseases and clinical signifi-cance. Am J Med. 1995;98:566–71.
   PubMed Web of Science ®Google Scholar
• Koorts AM, Viljoen M. Fenitin and ferritin isoforms I: structure-function relationships, synthesis, degradation and secretion. Arch Physiol Biochem. 2007;113(1):30–54.
   PubMedGoogle Scholar
• Koorts AM, Viljoen M. Fenitin and ferritin isoforms II: protec-tion against uncontrolled cellular proliferation, oxidative damage and inflammatory processes. Arch Physiol Biochem. 2007; 113(1):55–64.
   Google Scholar
• Emery P, Gabay C, Kraan M, Gomez-Reino J. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int. 2007; 27:793–806.
   Google Scholar
• Matsui T, Kuga Y, Kaneko A, et al. Disease Activity Score 28 (DA528) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DA528 using erythrocyte sedimentation rate in a large observa-tional cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis. 2007;66:1221–6.
   PubMed Web of Science ®Google Scholar
• Paulus HE, Brahn E. Is erythrocyte sedimentation rate the pref-erable measure of the acute phase response in rheumatoid arthritis? [editorial]. J Rheumatol. 2004;31(5):838–40.
   Google Scholar
• Shovman 0, Gilburd B, Zandman-Goddard G, et al. The diag-nostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinases-3, rheumatoid factor, erythrocyte sedimenta-tion rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis. Clin Dev Immunol. 2005;12(3): 197–202.
   Google Scholar
• Young-Min S, Cawston T, Marshall N, et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and per-form well compared with traditional markers. Arthritis Rheum. 2007 ;56(10) : 3236–47.
   Google Scholar
• Ates A, Tfirkopar N, Olmez U, et al. Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers. Rheumatol Int. 2007;27:715–22.
   PubMedGoogle Scholar
• Hameed B, Pilcher J, Heron C, Kiely PD. The relation between composite ultrasound measures and the DA528 score, its com-ponents and acute phase markers in adult RA. Rheumatology. 2008;47:476–80.
   PubMed Web of Science ®Google Scholar
• Badolato R, Oppenheim JJ. Role of cytokines, acute-phase pro-teins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum. 1996;26(2):526–38.
   PubMedGoogle Scholar
• Cutolo M, Montecucco CM, Cavagna L, Caporali R, Capellino S, Montagna P, et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis. 2006;65(11):1438–43.
   Google Scholar
• Karlson EW, Chibnik LB, Tworoger SS, Lee IM, Buring JE, Shadick NA. Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum. 2009;60(3):641–52.
   PubMedGoogle Scholar
• Vignes S, Le Moël G, Fautrel B, Wechsler B, Godeau P, Piette JC. Percentage of glycosilated serum ferritin remains low throughout the course of adult-onset Still's disease. Ann Rheum Dis. 2000;59:347–50.
   Google Scholar
• Hamidou MA, Denis M, Barbarot S, Boutoille D, Belizna C, Le Moël G. Usefulness of glycosilated ferritin in atypical pre-sentations of adult-onset Still's disease (letter). Ann Rheum Dis. 2004;63:605.
   PubMedGoogle Scholar
• Jung SY, Park MC, Park YB, Lee SK. Serum amyloid A as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J. 2007;48(2):218–24.
   Google Scholar
• Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F. Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine. 2007;74:249–53.
   Google Scholar
• Kaya T, Bal S, Gunaydin R. Relationship between the severity of enthesitis and clinical and laboratory parameters in patients with ankylosing spondylitis. Rheumatol Int. 2007;27:323–7.
   Google Scholar
• Yildirim K, Erdal A, Karatay S, Melikoglu MA, Ugur M, Senel K. Relationship between some acute phase reactants and the bath ankylosing spondylitis disease activity index in patients with ankylosing spondylitis. South Med J. 2004;97(4):350–3.
   PubMed Web of Science ®Google Scholar
• Lange U, Boss B, Teichmann J, Klör HU, Neeck G. Serum Amyloid A-an indicator of inflammation in ankylosing spon-dylitis. Rheumatol Int. 2000;19:119122.
   Google Scholar
• Visvanathan S, Wagner C, Marini JC, et al. Inflammatory bio-markers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis. 2008;67:511–7.
   PubMed Web of Science ®Google Scholar
• Romero-Sánchez C, Robinson WH, Tomooka BH, et al. Identi-fication of acute phase reactants and cytokines useful for moni-toring infliximab therapy in ankylosing spondylitis. Clin Rheumatol. 2008;27:1429–35.
   Google Scholar
• Roodpeyma S, Karnali Z, Zare R. Rheumatic fever: the rela-tionship between clinical manifestations and laboratory tests. J Pediatr Child Health. 2005;41:97–100.
   Google Scholar
• Ellis ME, Ralston S. The ESR in the diagnosis and management of the polymyalgia rheumatica/giant-cell arteritis syndrome. Ann Rheum Dis. 1983;42:168–70.
   PubMed Web of Science ®Google Scholar
• Helfgot S, Kieval RI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthritis Rheum. 1996; 39:304–7.
   Google Scholar
• Caliani L, Paira SO. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate: comment on the article by Helgot and Kieval (letter). Arthritis Rheum. 1997;40(9):1725–6.
   Google Scholar
• Cimmino MA, Accardo S, Scudeletti M, Indiveri F. The diag-nosis of polymyalgia rheumatica in patients with a low erythro-cyte sedimentation rate: comment on the article by Helfgot and Kieval (letter). Arthritis Rheum. 1997;40(9):1726–7.
   Google Scholar
• Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum. 2009;59(12): 1814–20.
   Google Scholar
• Gitlin JD, Colten HR. Molecular biology of the acute-phase plasma proteins. In: Pick E, Landy M, editors. Lymphokines, vol. 14. San Diego: Academic Press; 1987. p. 123–53.
   Google Scholar